Antibiotic News and Research

RSS

Antibiotics are drugs used to treat infections caused by bacteria and other microorganisms.

Accelr8 presents initial ICU pilot study results at ATS International Conference

Accelr8 Technology Corporation announced that clinical investigators led by Ivor S. Douglas, MD/FRCP (UK) from Denver Health presented initial ICU pilot study results at the 2011 ATS International Conference.

17 May 2011

Researchers discover bed bugs with MRSA in lower-income area residents

As if the recent resurgence of bed bugs wasn't bad enough, Canadian researchers have found some of the little blood-sucking critters carrying methicillin-resistant Staphylococcus aureus, the potentially deadly superbug known as MRSA.

17 May 2011

Eli Lilly responds to Amylin's exenatide lawsuit

Eli Lilly and Company has provided additional perspective in response to Amylin Pharmaceuticals, Inc.'s lawsuit filed in the United States District Court for the Southern District of California.

17 May 2011

Linezolid more effective than vancomycin in treating ventilated patients with MRSA pneumonia: Study

The antibiotic linezolid may be more effective than vancomycin in treating ventilated patients who develop methicillin-resistant Staphylococcus aureus (MRSA) pneumonia as a result of their ventilation, according to a study conducted globally by American and French researchers.

17 May 2011

FDA warns consumers about look like antimicrobial dietary supplements

The FDA is warning consumers not to use products marketed as dietary supplements that also claim to be antimicrobial (antibiotic, antifungal or antiviral) drugs. These illegal products are falsely promoted with claims to treat illnesses such as upper respiratory infections, sinusitis, pneumonia, bronchitis and the common cold.

16 May 2011

MRSA superbug detected in bed bugs and supermarket meats: Report

Scientists have made an alarming discovery. They have found that bedbugs can carry the staph “superbug” MRSA (Methicillin-Resistant Staphylococcus aureus).

15 May 2011

PCR testing for B. burgdorferi bacteria in joint fluid may confirm Lyme arthritis diagnosis

New research shows that polymerase chain reaction testing for Borrelia burgdorferi DNA—the spirochetal bacteria transmitted by deer ticks—in joint fluid may confirm the diagnosis of Lyme arthritis, but is not a reliable indicator for active joint infection in patients whose arthritis persists after antibiotic therapy. Findings of this study are published in Arthritis & Rheumatism, a journal of the American College of Rheumatology.

13 May 2011

Shared wind instruments may cause sickness

Germs survive for several days in wind instruments including the clarinet, flute, and saxophone, according to a pilot study published in the International Journal of Environmental Health Research. The researchers, led by Stuart Levy, MD, of Tufts University School of Medicine, urge proper cleaning of these instruments.

13 May 2011

Two DIFICID Phase 3 trial data in C. difficile infection presented at AGS Annual Meeting

Optimer Pharmaceuticals today announced the presentation of an additional analysis of data from the company's two Phase 3 clinical trials of DIFICID, an investigational antibiotic for the treatment of Clostridium difficile Infection, at the American Geriatric Society (AGS) Annual Meeting held in National Harbor, Maryland.

13 May 2011

Tips for fighting drug-resistant superbugs

Superbug CRKP is just the latest in emerging strains of drug-resistant bacteria. While new drugs to combat these stealthy microbes like MRSA and CRKP remain in development what can we do to prevent catching and spreading these dangerous bugs?.

13 May 2011

New clinical data affirms safety profile of PolyMedix's PMX-30063 in treatment of Staph infections

PolyMedix, Inc., an emerging biotechnology company focused on developing new therapeutic drugs to treat life-threatening infectious diseases and acute cardiovascular disorders, presented new clinical and pre-clinical data related to the safety and efficacy of its novel, lead defensin-mimetic antibiotic, PMX-30063.

12 May 2011

CrystalGenomics receives draft CSR for CG400549 Phase I MAD study in Staph infections

CrystalGenomics, Inc., a biopharmaceutical company with 3 clinical stage candidates, has announced today that the draft Clinical Study Report from CG400549's Phase I Multiple Ascending Dose Study has just been received.

12 May 2011

Sugar boosts effectiveness of first-line antibiotics against chronic bacterial infections

James Collins, a pioneering researcher in the new field of systems biology and a MacArthur Genius, says: "You know the old saying: 'a spoonful of sugar makes the medicine go down?' This is more like 'a spoonful of sugar makes the medicine work.'

12 May 2011

ViroPharma, Halozyme sign license deal to develop Cinryze against hereditary angioedema

Halozyme Therapeutics, Inc. and ViroPharma Incorporated, today announced the signing of a worldwide exclusive licensing agreement for the use of rHuPH20 in the development of a subcutaneous formulation of Cinryze .

12 May 2011

China Pharma first quarter revenue increases 20% to $18.1 million

China Pharma Holdings, Inc., a fully-integrated specialty pharmaceuticals company in China, today announced financial results for the quarter ended March 31, 2011.

11 May 2011

Two DIFICID Phase 3 trial data in C. difficile presented at DDW conference

Optimer Pharmaceuticals, Inc. today announced the presentation of two abstracts at the 2011 Digestive Disease Week conference highlighting additional analyses of data from Phase 3 trials of DIFICID, an investigational product for the treatment of Clostridium difficile infection.

11 May 2011

Two DIFICID Phase 3 study data in C. difficile presented at ECCMID conference

Optimer Pharmaceuticals, Inc. today announced the presentation of two abstracts at the 21st European Congress of Clinical Microbiology and Infectious Diseases conference in Milan, Italy highlighting additional analyses of the Phase 3 data of DIFICID for the treatment of Clostridium difficile infection.

11 May 2011

Novel two-drug combination cures young patient with extensively drug-resistant tuberculosis

Belgian physicians report they have cured a young patient with extensively drug-resistant tuberculosis (XDR-TB) using a novel two-drug combination developed by researchers at Albert Einstein College of Medicine of Yeshiva University. The report, published in the Pediatric Infectious Disease Journal, marks the first known clinical use of this treatment for XDR-TB, the most deadly form of the disease.

11 May 2011

16-year-old uses supercomputing network to invent new drug cocktail for cystic fibrosis

While many 16-year-olds are content with PlayStation, Toronto-area student Marshall Zhang used the Canadian SCINET supercomputing network to invent a new drug cocktail which could one day help treat cystic fibrosis.

11 May 2011

NTC, Aldevron partner to manufacture first plasmid DNA-based genetic cosmetic

Nature Technology Corporation "NTC" and Aldevron today announced a joint effort to manufacture the world's first plasmid DNA-based genetic cosmetic for Gene Facelift.

11 May 2011

Antibiotic News and Research

Further Reading

Accelr8 presents initial ICU pilot study results at ATS International Conference

Researchers discover bed bugs with MRSA in lower-income area residents

Eli Lilly responds to Amylin's exenatide lawsuit

Linezolid more effective than vancomycin in treating ventilated patients with MRSA pneumonia: Study

FDA warns consumers about look like antimicrobial dietary supplements

MRSA superbug detected in bed bugs and supermarket meats: Report

PCR testing for B. burgdorferi bacteria in joint fluid may confirm Lyme arthritis diagnosis

Shared wind instruments may cause sickness

Two DIFICID Phase 3 trial data in C. difficile infection presented at AGS Annual Meeting

Tips for fighting drug-resistant superbugs

New clinical data affirms safety profile of PolyMedix's PMX-30063 in treatment of Staph infections

CrystalGenomics receives draft CSR for CG400549 Phase I MAD study in Staph infections

Sugar boosts effectiveness of first-line antibiotics against chronic bacterial infections

ViroPharma, Halozyme sign license deal to develop Cinryze against hereditary angioedema

China Pharma first quarter revenue increases 20% to $18.1 million

Two DIFICID Phase 3 trial data in C. difficile presented at DDW conference

Two DIFICID Phase 3 study data in C. difficile presented at ECCMID conference

Novel two-drug combination cures young patient with extensively drug-resistant tuberculosis

16-year-old uses supercomputing network to invent new drug cocktail for cystic fibrosis

NTC, Aldevron partner to manufacture first plasmid DNA-based genetic cosmetic

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest News